Saladeaula.abitep.com.br
Noninvasive Ventilation in Acute Cardiogenic
Pulmonary Edema: Systematic Review and
Online article and related content
Josep Masip; Marta Roque; Bernat Sánchez; et al.
current as of August 27, 2008.
JAMA. 2005;294(24):3124-3130 (doi:10.1001/jama.294.24.3124)
Topic collections
Quality of Care; Evidence-Based Medicine; Review; Critical Care/ Intensive CareMedicine; Adult Critical Care
Noninvasive Ventilation in
Acute Cardiogenic Pulmonary Edema
Systematic Review and Meta-analysis
Context In patients with acute cardiogenic pulmonary edema noninvasive ventila-
tion may reduce intubation rate, but the impact on mortality and the superiority of
Bernat Sa´nchez, MD
one technique over another have not been clearly established.
Rafael Ferna´ndez, MD
Objective To systematically review and quantitatively synthesize the short-term effect
of noninvasive ventilation on major clinical outcomes.
Mireia Subirana, RN
Data Sources MEDLINE and EMBASE (from inception to October 2005) and Coch-
Jose´ Angel Expo´sito, BSc
rane databases (library issue 4, 2005) were searched to identify relevant randomized
controlled trials and systematic reviews published from January 1, 1988, to October
ONINVASIVE VENTILATION
(NIV) is a modality of venti-
Study Selection and Data Extraction Included trials were all parallel studies com-
latory support without endo-
paring noninvasive ventilation to conventional oxygen therapy in patients with acute pul-
tracheal intubation and seda-
monary edema. Comparisons of different techniques, either continuous positive airway
tion that has demonstrated to be useful
pressure (CPAP) or bilevel noninvasive pressure support ventilation (NIPSV), were also
in several forms of respiratory failure. In
patients with severe exacerbation of
Data Synthesis Fifteen trials were selected. Overall, noninvasive ventilation signifi-
chronic obstructive pulmonary disease,
cantly reduced the mortality rate by nearly 45% compared with conventional therapy
it has been shown to reduce mortal-
(risk ratio [RR], 0.55; 95% confidence interval [CI], 0.40-0.78;
P=.72 for heterogene-
ity.1,2 In the setting of acute pulmonary
ity). The results were significant for CPAP (RR, 0.53; 95% CI, 0.35-0.81;
P=.44 for het-
edema, NIV has been shown to reduce
erogeneity) but not for NIPSV (RR, 0.60; 95% CI, 0.34-1.05;
P=.76 for heterogeneity),
the intubation rate in several random-
although there were fewer studies in the latter. Both modalities showed a significant
ized trials, either using continuous posi-
decrease in the "need to intubate" rate compared with conventional therapy: CPAP (RR,0.40; 95% CI, 0.27-0.58;
P=.21 for heterogeneity), NIPSV (RR, 0.48; 95% CI, 0.30-
tive airway pressure (CPAP)3-8 or bi-
0.76;
P=.24 for heterogeneity), and together (RR, 0.43; 95% CI, 0.32-0.57;
P=.20 for
level noninvasive pressure support
heterogeneity). There were no differences in intubation or mortality rates in the analysis
ventilation (NIPSV).8,9 The technique of
of studies comparing the 2 techniques.
CPAP is simpler and may be performed
Conclusions Noninvasive ventilation reduces the need for intubation and mortality
with an oxygen source connected to a
in patients with acute cardiogenic pulmonary edema. Although the level of evidence
tight-fitting face mask or helmet, with an
is higher for CPAP, there are no significant differences in clinical outcomes when com-
expiratory valve to maintain constant
paring CPAP vs NIPSV.
positive intrathoracic pressure. Con-
versely, NIPSV is more complex, re-quires a ventilator to provide 2 levels of
tice,10,11 but its use is often based
ity, and considerable controversy
pressure: one to assist patients with in-
more on perceived efficacy than on
remains over which technique is
spiratory positive airway pressure (IPAP)
scientific evidence.11 This may be
superior to the other.12,13
and the other, like CPAP, to maintain ex-
explained because no single trial has
We undertook a systematic review
piratory positive pressure (EPAP).
shown an impact in hospital mortal-
to investigate the effect of NIV on the
With widespread adoption of NIV
in patients with acute and chronic
Author Affiliations: ICU Department, Hospital Dos de
Medicina Intensiva, Hospital de Sabadell, Corporacio´
respiratory failure over the last 2
Maig Consorci Sanitari Integral, University of Barce-
Parc Taulı´, Sabadell (Dr Ferna´ndez), Spain.
decades, acute pulmonary edema is
lona (Drs Masip and Sa´nchez) and Iberoamerican Coch-
Corresponding Author: Josep Masip, MD, ICU De-
currently the second most common
rane Center, Hospital de la Santa Creu i Sant Pau, Uni-
partment, Hospital Dos de Maig Consorci Sanitari In-
versitat Auto´noma de Barcelona (Mss Roque and
tegral Barcelona, University of Barcelona, Dos de Maig
indication for NIV in clinical prac-
Subirana and Mr Expo´sito), Barcelona, and Servei de
301, 08025 Barcelona, Spain (
[email protected]).
3124 JAMA, December 28, 2005—Vol 294, No. 24 (Reprinted)
2005 American Medical Association. All rights reserved.
NONINVASIVE VENTILATION IN ACUTE CARDIOGENIC PULMONARY EDEMA
main outcomes (intubation and mor-tality) comparing the 2 techniques to
Figure 1. Flow Diagram of Trial Selection
each other and to conventional oxy-
559 Trials Identified as Potentially Relevant
gen therapy.
and Screened for Retrieval
39 CENTRAL Database
199 EMBASE Database321 MEDLINE Database
532 Trials Excluded as Not Relevant, Not Randomized
We aimed to identify all randomized con-
Controlled Trial, or Duplicated
trolled trials assessing the efficacy of NIV
27 Retrieved for More Detailed Evaluation
in patients with acute pulmonary edema.
11 Trials Excluded
1 Design Containing Inadequate Adjusted Planned
The electronic search strategy applied
standard filters for identification of ran-
2 Crossover Design18,191 Out-of-Hospital Setting With Inappropriate Allocation20
domized clinical trials. Databases
2 Duplicated Data6,23
searched were the Cochrane Central Reg-
1 Subgroup of Patients With Acute Respiratory Failure213 Abstract Proceeding, Unpublished as a Full Paper24-26
ister of Controlled Trials (CENTRAL,
1 Published in Chinese27
The Cochrane Library Issue 4, 2005),
16 Potentially Appropriate Trials to Be
MEDLINE (from inception to October
Included in the Meta-analysis
2005), and EMBASE (from inception to
1 Trial Excluded Because No Available Data for
Outcomes of Interest28
October 2005). We did not apply lan-guage restrictions. In addition to the elec-
15 Trials Included in the
tronic search, we checked out cross-
15 With Outcome Data on Need to Intubate15 With Hospital Mortality Data
references from original articles and
14 With Myocardial Infarction Data
reviews and sometimes contactedauthors to obtain additional unpub-lished data. Our search included the fol-
respiratory failure were excluded, as
The primary outcomes for the in-
lowing:
continuous positive airway pres-
were studies published only in ab-
cluded trials were treatment failure, en-
sure (Medical Subject Headings [MeSH]);
stract form and those written in a non-
dotracheal intubation, myocardial in-
continuous positive airway*;
biphasic
accessible language after failure to ob-
farction, resolution time, therapeutical
intermittent positive airway;
bilevel posi-
tain more complete data.
success at 2 hours, 48-hour mortality, in-
tive airway*;
noninvasive ventilatory-
hospital mortality, and specific labora-
assistance apparatus;
noninvasive sup-
tory or physiological parameters. The pri-
port ventilation;
noninvasive ventilat*;
The initial selection was performed by
mary outcomes for the present study
non-invasive ventilat*;
CPAP;
Bipap;
pul-
distributing references among pairs of
were treatment failure and in-hospital
monary edema (MeSH);
acute pulmo-
independent reviewers. A full-text copy
mortality because all the included trials
nary edema;
heart failure, congestive
of all studies of possible relevance was
presented data about these items. How-
(MeSH);
edema, cardiac (MeSH);
acute
obtained and data from each study was
ever, treatment failure was often re-
cardiogenic edema linked with
random-
extracted independently by paired re-
ported using different definitions. It was
ized controlled trial OR
controlled clini-
viewers, using a prestandardized data
endotracheal intubation in some stud-
cal trial OR
randomized controlled trials
abstraction form. Data extracted were
ies, "criteria for intubation" (which was
OR
random allocation OR
double-blind
checked by a third reviewer ( J.M. or
not necessarily performed) in others, and
method OR
single-blind method OR
clini-
M.R.) for accuracy. The reviewers de-
some arbitrary clinical or blood gas cri-
cal trial OR
clinical trials in various com-
cided which trials fitted the inclusion
teria at different intervals of time in oth-
criteria focusing on study design, pa-
ers. For this item, we finally decided to
tients' characteristics, protocol of the in-
select the variable "need to intubate,"
Selection of Studies
terventions, outcomes measured, and
which included those patients who were
We restricted the analysis to parallel
main results. Any disagreement appear-
intubated and those who needed to be
randomized trials comparing NIV to
ing during the process was solved by
intubated but were not, either due to suc-
conventional oxygen therapy or to an-
discussion and team consensus.
cessful rescue NIV, patient's refusal, or
other NIV modality. Study designs con-
Methodological quality of the in-
a medical decision on account of seri-
taining inadequately adjusted planned
cluded trials was assessed collecting
ous comorbidities.
cointerventions and crossover trials
data on key domains related to valid-
Myocardial infarction was consid-
were not included. Studies that ana-
ity14,15: reporting of allocation conceal-
ered a secondary outcome in the pres-
lyzed the application of NIV in pa-
ment, description of an adequate ran-
ent study. This complication was com-
tients with acute pulmonary edema as
domization method, and specification
puted whether it was identified as the
a part of a group of patients with acute
of loss of subjects.
cause of acute pulmonary edema or was
2005 American Medical Association. All rights reserved.
(Reprinted) JAMA, December 28, 2005—Vol 294, No. 24
3125
NONINVASIVE VENTILATION IN ACUTE CARDIOGENIC PULMONARY EDEMA
diagnosed soon after admission. Pre-
poxemia was required for diagnosis,
preparing and maintaining Cochrane sys-
vious episodes of myocardial infarc-
whether assessed by pulse-oximetry or
tematic reviews. Although the main
tion were not counted. Other terms like
arterial blood gas samples.
analysis was made considering avail-
intensive care unit (ICU) length of stay,
able data as finally published by au-
hospital length of stay, one-year mor-
thors, an intention-to-treat sensitivity
tality, physiological measurements at
We summarized available data for all
analysis was also performed in order to
baseline and at 1 hour, and adverse ef-
trials reporting results on need to intu-
obtain more exact results, assuming that
fects were also collected but were not
bate or mortality, computing pooled risk
lost or withdrawn patients experienced
analyzed because there was a lack of this
ratios (RRs) and their respective 95%
outcomes (either need to intubate or
information in many of the studies.
confidence intervals (CIs) by means of
death). Three-arm trials were analyzed
Although there were heterogeneities
a fixed-effects meta-analysis model. We
as 2-arm separate trials in each compari-
in the definition of acute pulmonary
examined heterogeneity using a 2 test.
son, duplicating the control group data.
edema, it was generally described as dys-
All statistical analyses were performed
A sensitivity analysis was performed cor-
pnea of acute onset, with physical and
with Review Manager (Revman version
recting for this artificial sample size in-
radiological signs of pulmonary edema.
4.2 for Windows, Oxford, England), the
crease, showing no relevant differences
In addition, in almost all the studies hy-
Cochrane Collaboration's software for
with respect to the main analysis.
Table. Randomized Studies Analyzing Noninvasive Ventilation
Continuous Positive Airway Pressure vs Oxygen Therapy
Clinical outcomes
1 ICU in Australia
40 (39) Full face
In-hospital mortality
Takeda et al,29 1 ICU in Japan
30 (29) Full face or
Laboratory parameters
Measurement of plasma
1 ED and ICU in the
Clinical outcomes
Measurement of plasma
Laboratory parameters
Elderly patients (⬎75 y)
Noninvasive Pressure Support Ventilation vs Conventional Oxygen Therapy
40 (37) Full face
IPAP was adjusted to tidal
1 ED in the United
Prematurely interrupted
when the study by Mehtaet al35 was published
14.5/6.1, Mean Intubation
Post hoc analysis in
hypercapnic patients
Trials With 3 Study Groups
Full-face mask for CPAP and
2 EDs in the United
Success in ED (2 h)
Prehospital nitrates therapy
In-hospital mortality
83 (80) Full face
Continuous Positive Airway Pressure vs Noninvasive Pressure Support Ventilation
1 ED in the United
Prematurely stopped for
higher rate of AMI in
Bellone et al,36 1 ED in Italy
Study restricted to patients
Bellone et al,37 1 ED in Italy
Primary end point was AMI
Only nonischemic APE
Abbreviations: AMI, acute myocardial infarction; APE, acute pulmonary edema; CPAP, continuous positive airway pressure; ED, emergency department; EPAP, positive expiratory
airway pressure (equivalent to CPAP); ICU, intensive care unit; IPAP, inspiratory positive airway pressure; NIPSV, bilevel noninvasive pressure support ventilation.
*Numbers in parentheses denote the number of patients finally included after withdrawals.
3126 JAMA, December 28, 2005—Vol 294, No. 24 (Reprinted)
2005 American Medical Association. All rights reserved.
NONINVASIVE VENTILATION IN ACUTE CARDIOGENIC PULMONARY EDEMA
Publication bias was assessed apply-
Figure 2. Effects of Noninvasive Ventilation on Death
ing the Egger et al16 and Begg et al17 sta-tistical tests to the 2 main outcomes of
the included trials: intubation and in-
No. of Events/ Total No.
hospital mortality. Publication bias was
Noninvasive Control
studied separately for trials compar-
Continuous Positive Airway Pressure
ing NIV with control and for trials com-
Räsänen et al,3 1985
paring modalities of NIV.
Bersten et al,4 1991
Takeda et al,29 1997
Park et al,30 2001
Kelly et al,31 2002
Our initial electronic search identified
Crane et al,32 2004
L‘Her et al,7 2004
559 studies. Of these, 532 were ex-
Park et al,8 2004
cluded because they were not random-
Risk Ratio, 0.5395% Confidence Interval, 0.35-0.81
ized trials, did not evaluate NIV in pa-
tients with acute pulmonary edema,
P = .44 for Heterogeneity
Noninvasive Pressure Support Ventilation
were duplicated references, or were not
relevant. Twenty-seven studies were re-
Masip et al,9 2000
trieved for more detailed analysis, 11
Park et al,30 2001
of which were excluded. Two were ex-
Nava et al,34 2003
Crane et al,32 2004
cluded because of crossover de-
Park et al,8 2004
sign18,19; 1 for out-of-hospital setting
with inappropriate allocation20; 1 for re-
95% Confidence Interval, 0.34-1.05
P = .07
cruitment of patients with acute pul-
P = .76 for Heterogeneity
monary edema as a part of a series with
acute respiratory failure21; 1 for study
95% Confidence Interval, 0.40-0.78
P <.001
design containing inadequately ad-
P = .72 for Heterogeneity
justed planned cointerventions22; 2 for
duplicated publications, partial6 or com-
Risk Ratio (95% Confidence Interval)
plete23; 3 for results reported exclu-sively in proceedings,24-26 and 1 study
Data markers are proportional to the amount of data contributed by each trial.
published in a nonaccessible language.27
The flow diagram of the trial selec-
tory tract infection, arrhythmia, vol-
age IPAP ranged from 14.5 to 20 cm H2O
tion process is shown in
FIGURE 1. Six-
ume overload, or treatment noncom-
with 15 cm H2O being the most re-
teen studies were selected, one of which
pliance, accounted for 28% of the cases.
peated value. Conversely, EPAP was set
was finally excluded because the re-
Causes of death were reported in few
at 5 cm H2O in most trials. Ventilators
ported outcomes did not meet our se-
studies5,8,9,30,35,36 and half of the cases
used for NIPSV differed substantially
lection criteria.28 Thus, we included 15
were related to shock.
from one study to another. Intensive care
trials in the meta-analysis.3-5,7-9,29-37
All trials used full face masks (oro-
unit ventilators were used in one trial,9
nasal) but nasal masks were also used
whereas specific NIV portable ventila-
in 27% of them. Nine studies com-
tors were used in the others. Early stud-
Trial characteristics are summarized in
pared CPAP with conventional oxygen
ies used very simple devices.
the
TABLE. Although all were pub-
therapy,3-5,7,8,29-32 3 of them involved in
In general, methodological quality
lished in English, they represent an in-
a 3-branch design concomitantly ana-
was acceptable. Eleven out of 15 trial
ternational experience, including data
lyzing NIPSV.8,30,32 Six studies com-
reports described the use of appropri-
from 11 countries. Three studies were
pared NIPSV with conventional oxy-
ate randomization methods, mainly
multiple-center trials, whereas the oth-
gen therapy,8,9,30,32-34 3 being those
ers were conducted in a single center.
mentioned with 3 branches. Finally,
lists.4,7-9,31-37 Nine of the studies de-
Causes of acute pulmonary edema
6 studies compared CPAP with
scribed the use of a concealed alloca-
were reported in 11 of the stud-
NIPSV8,30,32,35-37 and again, 3 of them also
tion method, all but one using sealed
ies3-5,7-9,29,30,34,36,37 and were described as
compared conventional therapy. The
envelopes with or without external ran-
acute coronary syndrome in 203 (31%)
CPAP level used in these trials ranged
domization,3,7-9,31,32,34,36,37 and all stud-
of the patients, hypertension in 178
from 2.5 to 12.5 cm H2O although the
ies reported the number of patients, if
(27%), or worsening heart failure in 92
most frequent pressure was 10 cm H2O.
any, lost to follow-up. Nine studies in-
(14%). Other precipitants like respira-
The level of NIPSV was variable. Aver-
cluded sample-size calculations.4,7-9,33-37
2005 American Medical Association. All rights reserved.
(Reprinted) JAMA, December 28, 2005—Vol 294, No. 24
3127
NONINVASIVE VENTILATION IN ACUTE CARDIOGENIC PULMONARY EDEMA
heterogeneity), and 49% for NIPSV (RR,
Figure 3. Effects of Noninvasive Ventilation on Need to Intubate
0.51; 95% CI, 0.33-0.78;
P = .42 for
Need to Intubate,
No. of Events/Total No.
The overall myocardial infarction rate
Noninvasive Control
for NIV was 78 (22.5%) of 346, which
was similar to that observed for conven-
Continuous Positive Airway Pressure
Räsänen et al,3 1985
tional therapy, 78 (26.8%) of 292 (RR,
Bersten et al,4 1991
0.89; 95% CI, 0.69-1.17;
P=.99 for het-
erogeneity). In about 60% of the cases,
Takeda et al,29 1997
Park et al,30 2001
myocardial infarction was reported as a
Kelly et al,31 2002
cause of acute pulmonary edema. Ad-
Crane et al,32 2004
verse effects like vomiting, abdominal
L‘Her et al,7 2004
Park et al,8 2004
distention, claustrophobia, or skin re-
actions were infrequent and were re-
95% Confidence Interval, 0.27-0.58
P <.001
ported only in a few patients.
P = .21 for Heterogeneity
Comparison Between CPAP and
Noninvasive Pressure Support Ventilation
NIPSV. Six studies compared CPAP with
Masip et al,9 2000
NIPSV, and 3 of these also compared the
Park et al,30 2001
2 techniques with conventional treat-
Nava et al,34 2003
ment. Overall, the number of patients
Crane et al,32 2004
included in these studies was 219. No
Park et al,8 2004
differences were seen in the main out-
95% Confidence Interval, 0.30-0.76
comes, mortality and need-to-intubate
P = .002
P = .24 for Heterogeneity
rate, in the studies comparing CPAP to
NIPSV (
FIGURE 4). Although a slight ten-
95% Confidence Interval, 0.32-0.57
dency in favor of NIPSV was observed
P <.001
P = .20 for Heterogeneity
in relation to the intubation rate, no di-rectional trend in mortality was seen.
Risk Ratio (95% Confidence Interval)
COMMENT
This systematic review and meta-
Nine of the studies found significant im-
When the analysis was performed by
analysis demonstrates the effectiveness
provement in at least 1 of the main out-
intention-to-treat, computing with-
of noninvasive ventilation to reduce in-
comes for which the trial was designed,
drawals as events, RRs and 95% CIs
tubation rate and mortality in patients
whereas all the studies found sig-
from a random-effects model did not
with acute pulmonary edema. In a pre-
nificant improvement in secondary
differ significantly, showing a global
vious systematic review published in
reduction in mortality risk of 43% for
1998,38 CPAP was associated with a de-
The analysis of the publication bias
NIV (RR, 0.57; 95% CI, 0.41-0.79;
crease in need for intubation (risk dif-
yielded no significant results for either
P = .73 for heterogeneity), which was
ference −26%) and a trend to decrease
test or comparison group.
46% for CPAP (RR, 0.54; 95% CI,
mortality, but there was insufficient evi-
0.36-0.82;
P = .40 for heterogeneity)
dence on the effectiveness of NIPSV,
and 37% for NIPSV (RR, 0.63; 95% CI,
either compared with standard therapy
NIV and Conventional Oxygen Ther-
0.37-1.06;
P=.87 for heterogeneity).
or CPAP, because there were no ran-
apy. Pooled data included 727 pa-
Taken together the 2 NIV modali-
domized trials at that time. Neverthe-
tients. Overall, NIV significantly re-
ties demonstrated a significant 57% re-
less, in the last 7 years, many studies have
duced the risk of mortality compared
duction in the need-to-intubate risk
been published evaluating either CPAP
with conventional oxygen therapy
(
P⬍.001;
FIGURE 3). The decrease was
or NIPSV in patients with acute pulmo-
(
P⬍.001;
FIGURE 2). The results were
statistically significant either for CPAP
nary edema. Probably as a result of in-
significant for CPAP, whereas NIPSV
or NIPSV. Similar results were seen
creased sample size, our meta-analysis in-
tended toward a 40% reduction in the
when the analysis was performed by in-
cluding these trials has clearly reinforced
risk of mortality (
P = .07). However,
tention to treat: 56% reduction in need-
the role of CPAP in comparison with
the number of patients studied with
to-intubate risk for pooled data (RR,
conventional therapy, showing a dra-
NIPSV was lower than with CPAP and
0.44; 95% CI, 0.34-0.59;
P=.31 for het-
matic reduction in the need for intuba-
the proportional weight for NIPSV in
erogeneity), 60% reduction for CPAP
tion (reduction in risk 60%) and a de-
the pooled data analysis was only 35%.
(RR, 0.40; 95% CI, 0.28-0.58;
P=.23 for
crease in mortality (47%), which reached
3128 JAMA, December 28, 2005—Vol 294, No. 24 (Reprinted)
2005 American Medical Association. All rights reserved.
NONINVASIVE VENTILATION IN ACUTE CARDIOGENIC PULMONARY EDEMA
statistical significance. Parallel to these
Figure 4. Effects of Continuous Positive Airway Pressure vs Noninvasive Pressure Support
results, NIPSV demonstrated a similar re-
duction in the need for intubation (52%)and a trend to decrease mortality in com-
No. of Events/Total No.
Continuous Positive
Noninvasive Pressure
parison with conventional therapy. As in
Support Ventilation
the previous meta-analysis with CPAP,38
Source or Subcategory
Mehta et al,35 1997
the impact of NIPSV on mortality did not
Park et al,30 2001
reach statistical significance, possibly be-
Bellone et al,36 2004
cause the number of patients included
Crane et al,32 2004
in the model remains underpowered to
Park et al,8 2004
Bellone et al,37 2005
demonstrate a substantial decrease inmortality. Although additional re-
Risk Ratio, 0.9095% Confidence
search would resolve this issue, current
evidence on the effectiveness of NIV, es-
P = .82
P = .34 for Heterogeneity
pecially CPAP, over conventional treat-
Need to Intubate,
No. of Events/Total No.
ment supports the use of this technique
Source or Subcategory
as standard therapy and further com-
Mehta et al,35 1997
parisons between NIPSV and conven-
Park et al,30 2001
tional oxygen therapy would not be con-
Bellone et al,36 2004
sidered acceptable.
Crane et al,32 2004
In the comparison of NIV modali-
Park et al,8 2004
Bellone et al,37 2005
ties, NIPSV has the potential advantageover CPAP of assisting the respiratory
Risk Ratio, 1.4595% Confidence
muscles during inspiration, which would
result in faster alleviation of dyspnea and
P = .39
P = .63 for Heterogeneity
exhaustion.12 Nevertheless, these physi-
ological benefits did not translate into pri-
Risk Ratio (95% Confidence Interval)
mary outcomes in our meta-analysis,which did not find differences betweenCPAP and NIPSV in terms of intuba-
technique offers advantage over the
is less dependent on the experience or
tion or mortality. This equivalence re-
other and what subset of patients would
the device and shows much lower vari-
mained whether some nonpublished
benefit more with either one of these
ability in the studies. Third, besides ame-
trials24,25 not included in the analysis,
techniques remains unresolved.13
liorating fatigue, the main advantage of
were incorporated into the model (data
The present meta-analysis has sev-
NIV is to avoid intubation and its asso-
available on request). In addition, even
eral limitations. First, criteria for diag-
ciated complications, subsequently re-
in patients with acute pulmonary edema
nosis of acute pulmonary edema are not
ducing the mortality rate. Several stud-
and hypercapnia, a condition usually as-
well established. In the new guidelines
ies used rescue NIV, sometimes NIPSV
sociated with muscle fatigue, a recent
on the diagnosis and treatment of acute
in CPAP groups or either NIPSV or
study did not demonstrate differences be-
heart failure proposed by the Euro-
CPAP in conventional groups. This
tween these techniques either.37 Hyper-
pean Society of Cardiology,40 2 types of
might have introduced some conserva-
capnic patients were expected to be the
acute pulmonary edema are recog-
tive bias in the estimation of the mor-
target population for NIPSV for physi-
nized: hypertensive crisis and non–
tality rate. Fourth, although our analy-
ological reasons and especially after the
hypertensive pulmonary edema. The
sis did not find significant publication
favorable results in the post hoc analy-
prognosis in terms of intubation and
bias, this result must be taken with cau-
ses of some studies using NIPSV.34,39
mortality differs41 and the proportion of
tion due to the low power of tests ana-
The incidence of myocardial infarc-
each type of acute pulmonary edema in-
lyzing this issue when the number of
tion for the interventional therapies ana-
cluded in the studies was not well de-
trials is small. Finally, although many
lyzed in the studies was similar. Al-
fined. Second, the characteristics of the
trials of this meta-analysis included a
though a preliminary study35 described
ventilators (displays, leakage compen-
small sample size, more than half were
a higher rate of acute myocardial infarc-
sation, FiO2 range, trigger, etc), the level
powered enough to demonstrate signifi-
tion with NIPSV, no other trial found
of NIPSV used and the experience of the
cant differences between interventions
this incidence and a recent study, spe-
teams were relatively different in the
in the main outcomes. The limited size
cifically addressing this issue, showed no
trials and all of these variables may in-
of some of these trials, however, rein-
differences between both techniques.36
fluence the results of this technique.42
forces the necessity of our meta-
Therefore, the question of whether one
This is not the case for CPAP because it
analysis. In addition, it should be men-
2005 American Medical Association. All rights reserved.
(Reprinted) JAMA, December 28, 2005—Vol 294, No. 24
3129
NONINVASIVE VENTILATION IN ACUTE CARDIOGENIC PULMONARY EDEMA
tioned that the critical phase of acute
2. Ram FS, Picot J, Lightowler J, Wedzicha JA. Non-
acute cardiogenic pulmonary edema.
J Formos Med
invasive positive pressure ventilation for treatment of
pulmonary edema, when patients are eli-
respiratory failure due to exacerbations of chronic ob-
24. Bollaert PE, Sauder PH, Girard F, et al. Continuous
gible, may be extremely short because
structive pulmonary disease.
Cochrane Database Syst
positive airway pressure (CPAP) vs proportional assist
some patients may require immediate in-
ventilation (PAV) for noninvasive ventilation in cardio-
3. Ra¨sa¨nen J, Heikkla¨ J, Downs J, Nikki P, Va¨isa¨nen I,
genic pulmonary edema (CPE).
Am J Respir Crit Care
tubation or may rapidly ameliorate af-
Viitanen A. Continuous positive airway pressure by face
Med. 2002;165(suppl 8):A387.
ter starting medical therapy. This rapid
mask in acute cardiogenic pulmonary edema.
Am J
25. Liesching TN, Cromier K, Nelson D, Short K, Su-
cov A, Hill NS. Bilevel noninvasive ventilation vs con-
evolution has seriously limited the re-
4. Bersten AD, Holt AW, Vedig AE, Skowronski GA, Bag-
tinuous positive airway pressure to treat acute pulmo-
cruitment capacity of the studies.
goley CJ. Treatment of severe cardiogenic pulmonary
nary edema.
Am J Respir Crit Care Med. 2003;167(suppl
edema with continuous positive airway pressure deliv-
Despite these limitations our quan-
ered by face mask.
N Engl J Med. 1991;325:1825-1830.
26. Mackay CA, Mackay TW, Barr K, et al. Random-
titative systematic review of existing lit-
5. Lin M, Yang YF, Chiang HT, Chang MS, Chiang BN,
ized controlled trial of CPAP vs conventional therapy in
Cheitlin MD. Reappraisal of continuous positive air-
acute pulmonary edema.
Am J Respir Crit Care Med.
erature demonstrates that NIV re-
way pressure therapy in acute cardiogenic pulmonary
duces intubation rate and mortality in
edema.
Chest. 1995;107:1379-1386.
27. Hao CX, Luo XR, Liu YM. Treatment of severe car-
6. Takeda S, Nejima J, Takano T, et al. Effect of nasal
diogenic pulmonary edema with continuous positive air-
patients with acute pulmonary edema.
continuous positive airway pressure on pulmonary edema
way pressure by basal face mask.
Acta Academiae Me-
Noninvasive ventilation has recently
complicating acute myocardial infarction.
Jpn Circ J.
dicinae Jiangxi. 2002;42:48-50.
28. Moritz F, Benichou J, Vanheste M, et al. Boussig-
been categorized as class IIa, level of evi-
1998;62:553-558.
7. L'Her E, Duquesne F, Girou E, et al. Noninvasive con-
nac continuous positive airway pressure device in the
dence A, in the guidelines on the diag-
tinuous positive airway pressure in elderly cardiogenic
emergency care of acute cardiogenic pulmonary oe-
nosis and treatment for acute heart
pulmonary edema patients.
Intensive Care Med. 2004;
dema: a randomized pilot study.
Eur J Emerg Med. 2003;
failure by the European Society of Car-
8. Park M, Sangean MC, Volpe MC, et al. Random-
29. Takeda S, Takano T, Oqawa R. The effect of nasal
diology,40 based on some of the trials
ized, prospective trial of oxygen, continuous positive air-
continuous positive airway pressure on plasma endo-
way pressure, and bilevel positive airway pressure by
thelin-1 concentrations in patients with severe cardio-
analyzed in the present study.3-6,9,22,31,35
face mask in acute cardiogenic pulmonary edema.
Crit
genic pulmonary edema.
Anesth Analg. 1997;84:1091-
Given the results of our review, we
Care Med. 2004;32:2407-2415.
9. Masip J, Betbese´ AJ, Pa´ez J, et al. Non-invasive pres-
30. Park M, Lorenzi-Filho G, Feltrim MI, et al. Oxygen
think that NIV should be strongly con-
sure support ventilation versus conventional oxygen
therapy, continuous positive airway pressure, or non-
sidered as a first-line treatment.
therapy in acute cardiogenic pulmonary edema: a ran-
invasive bilevel positive pressure ventilation in the treat-
domized study.
Lancet. 2000;356:2126-2132.
ment of acute cardiogenic pulmonary edema.
Arq Bras
Author Contributions: Dr Masip had full access to all
10. Antonelli M, Conti G, Moro ML, et al. Predictors
of the data in the study and takes responsibility for
of failure of noninvasive positive ventilation in patients
31. Kelly CA, Newby DE, McDonagh TA, et al. Ran-
the integrity of the data and the accuracy of the data
with acute hypoxemic respiratory failure.
Intensive Care
domised controlled trial of continuous positive airway
pressure and standard oxygen therapy in acute pulmo-
Study concept and design: Masip, Roque, Sa´nchez,
11. Burns KE, Sinuff T, Adhhikari NK, et al. Bilevel non-
nary oedema.
Eur Heart J. 2002;23:1379-1386.
invasive positive pressure ventilation for acute respira-
32. Crane SD, Elliott MW, Gilligan P, Richards K, Gray
Acquisition of data: Masip, Roque, Sa´nchez, Subirana,
tory failure.
Crit Care Med. 2005;33:1477-1483.
AJ. Randomised controlled comparison of continuous
12. Wysocki M. Noninvasive ventilation in acute car-
positive airways pressure, bilevel non-invasive ventila-
Analysis and interpretation of data: Masip, Roque,
diogenic pulmonary edema: better than continuous posi-
tion, and standard treatment in emergency depart-
Sa´nchez, Subirana, Expo´sito
tive airway pressure?
Intensive Care Med. 1999;25:1-2.
ment in patients with acute cardiogenic pulmonary
Drafting of the manuscript: Masip.
13. Mehta S, Nava S. Mask ventilation and cardio-
oedema.
Emerg Med J. 2004;21:155-161.
Critical revision of the manuscript for important in-
genic pulmonary edema.
Intensive Care Med. 2005;
33. Levitt MA. A prospective, randomized trial of BIPAP
tellectual content: Masip, Roque, Sa´nchez, Ferna´ndez,
in severe acute congestive heart failure.
J Emerg Med.
14. Jadad AR, Moore RA, Carroll D, et al. Assessing the
quality of reports of randomized clinical trials: is blind-
34. Nava S, Carbone G, Dibatista N, et al. Noninva-
Statistical analysis: Masip, Roque.
ing necessary?
Control Clin Trials. 1996;17:1-12.
sive ventilation in cardiogenic pulmonary edema.
Am J
Obtained funding: Masip, Roque.
15. Schulz KF, Chalmers I, Hayes RJ, Altman D. Em-
Respir Crit Care Med. 2003;168:1432-1437.
Administrative, technical, or material support: Roque,
pirical evidence of bias.
JAMA. 1995;273:408-412.
35. Mehta S, Jay GD, Woolard RH, et al. Random-
Sa´nchez, Ferna´ndez, Subirana, Expo´sito.
16. Egger M, Smith GD, Schneider M, Minder C. Bias
ized, prospective trial of bilevel vs continuous positive
Study supervision: Masip, Roque, Ferna´ndez.
in meta-analysis detected by a simple, graphical test.
airway pressure in acute pulmonary edema.
Crit Care
Financial Disclosures: None reported.
Funding/Support: This project was funded in part by
17. Begg CB, Mazumdar M. Operating characteristics
36. Bellone A, Monari A, Cortellaro F, Vettorello M, Ar-
the nonprofit Agencia de Evaluacio´n de Tecnologı´as
of a rank correlation test for publication bias.
Biometrics.
lati S, Coen D. Myocardial infarction rate in acute pul-
Sanitarias, Instituto de Salud Carlos III, Fondo de In-
monary edema.
Crit Care Med. 2004;32:1860-1865.
vestigacio´n Sanitaria (FIS) PI04/90064. The grant cov-
18. Vaisanen IT, Rasanen J. Continuous positive air-
37. Bellone A, Vettorello M, Monari A, Cortellaro F, Coen
ered administrative material and a scholarship.
way pressure and supplemental oxygen in the treat-
D. Noninvasive pressure support ventilation vs continu-
Role of the Sponsor: Agencia de Evaluacio´n de Tec-
ment of cardiogenic pulmonary edema.
Chest. 1987;92:
ous positive airway pressure in acute hypercapnic pul-
nologı´as Sanitarias, Instituto de Salud Carlos III, Fondo
monary edema.
Intensive Care Med. 2005;31:807-811.
de Investigacio´n Sanitaria, did not participate in the
19. Chadda K, Annane D, Hart N, et al. Cardiac
38. Pang D, Keenan SP, Cook DJ, Sibbald WJ. The effect
design and conduct of the study, in the collection,
and respiratory effects of continuous positive airway
of positive pressure airway support on mortality and need
analysis, and interpretation of the data, or in the prepa-
pressure and noninvasive ventilation in acute cardiac
for intubation in cardiogenic pulmonary edema: a sys-
ration, review, or approval of the manuscript.
pulmonary edema.
Crit Care Med. 2002;30:2457-
tematic review.
Chest. 1998;114:1185-1192.
Acknowledgment: We thank Carolyn Newey (lan-
39. Rusterholtz T, Kempf J, Berton C, et al. Noninva-
guage editor at Institut de Recerca de l'Hospital de la
20. Craven RA, Singletary N, Bosken L, et al. Use of bi-
sive pressure support ventilation (NIPSV) with face mask
Santa Creu I Sant Pau, Barcelona) and Mitsi Ito (En-
level positive airway pressure in out-of-hospital patients.
in patients with acute pulmonary edema (ACPE).
In-
glish Essentials) for editing the manuscript and Joa-
Acad Emerg Med. 2000;7:1065-1068.
tensive Care Med. 1999;25:21-28.
quim Pa´ez (attending physician, ICU Department, Hos-
21. Cross AM, Cameron P, Kierce M, Ragg M, Kelly AM.
40. Nieminen MS, Bohm M, Cowie MR, et al. Execu-
pital Dos de Maig de Barcelona) for his constant support
Non-invasive ventilation in acute respiratory failure.
tive summary of the guidelines on the diagnosis and
throughout the project.
Emerg Med J. 2003;20:531-534.
treatment of acute heart failure.
Eur Heart J. 2005;26:
22. Sharon A, Shpirer I, Kaluski E, et al. High-dose in-
travenous isosorbide-dinitrate is safer and better than
41. Masip J, Pen˜a C, Figueras J, Pa´ez J, Sa´nchez B, Can-
Bi-PAP ventilation combined with conventional treat-
cio B. Hypertensive acute pulmonary edema.
Eur J Heart
1. Brochard L, Mancebo J, Wysocki M, et al. Nonin-
ment for severe pulmonary edema.
J Am Coll Cardiol.
Fail. 2005;4(suppl 1):11.
vasive ventilation for acute exacerbations of chronic ob-
42. Masip J, Pa´ez J, Betbese´ AJ, Vecilla F. Noninvasive
structive pulmonary disease.
N Engl J Med. 1995;333:
23. Lin M, Chiang HT. The efficacy of early continu-
ventilation for pulmonary edema in emergency room.
ous positive airway pressure therapy in patients with
Am J Respir Crit Care Med. 2004;169:1072-1073.
3130 JAMA, December 28, 2005—Vol 294, No. 24 (Reprinted)
2005 American Medical Association. All rights reserved.
Source: http://www.saladeaula.abitep.com.br/upload/slidesoff/vd_744f/revis%C3%A3o%20sistematica%20e%20meta%20an%C3%A1lise.pdf
The dysplastic nevus: From historical perspective to management in the modern era Part II. Molecular aspects and clinical management Keith Duffy, MD,a and Douglas Grossman, MD, PhDa,b Salt Lake City, Utah The following is a journal-based CME activity presented by the American Academy of Date of release: July 2012 Dermatology and is made up of four phases: Expiration date: July 2015
WATER-ACTIVITY TESTING Implementation of WaterActivity Testing to Replace KarlFischer Water Testing for Solid Oral-Dosage Forms Bob Snider, Peihong Liang, and Neil Pearson For solid oral- ost pharmacopeial monographs that have proce- dosage forms, water